Urea anticonvulsants

Definition and Pharmacological Relevance
Urea anticonvulsants refer to a specific subgroup of antiepileptic drugs (AEDs) that contain a urea or ureide chemical backbone, which pharmacologically contributes to their central nervous system (CNS) activity, particularly in the modulation of seizures. The term “ureide” is historically associated with barbituric acid derivatives and compounds structurally derived from phenylurea, phenylhydantoin, or carbamoylurea.

Though not commonly grouped as a standalone class in modern pharmacotherapy taxonomies, urea-based anticonvulsants share pharmacokinetic and pharmacodynamic properties related to their urea-derived moieties, often influencing voltage-gated sodium channels, T-type calcium channels, GABAergic neurotransmission, or glutamatergic excitability. These mechanisms are vital in controlling epileptic neuronal discharges.

This category includes structurally or functionally relevant drugs such as phenytoin, phenobarbital, primidone, ethotoin, and mephenytoin, which are sometimes collectively referred to as ureide anticonvulsants due to their shared derivation from barbituric acid (a ureide derivative).

---

Mechanism of Action

Urea anticonvulsants operate via multiple mechanisms, depending on the individual compound. Commonly involved actions include:

1. Voltage-gated sodium channel inhibition
   – Prolongs neuronal refractory period, preventing repetitive firing
   – Phenytoin, Mephenytoin

2. Potentiation of GABAergic activity
   – Enhances chloride influx and inhibitory neurotransmission
   – Phenobarbital, Primidone

3. Inhibition of T-type calcium channels
   – Particularly relevant in absence seizures
   – Ethosuximide (structural analogs)

4. Inhibition of glutamate release
   – Reduces excitatory neurotransmitter activity

Their cumulative effect is to raise the seizure threshold and suppress abnormal neuronal discharges without significant alteration of normal CNS activity at therapeutic doses.

---

Clinical Indications

These agents are primarily prescribed for:

• Generalized tonic-clonic seizures (grand mal)

• Partial (focal) seizures with or without secondary generalization

• Febrile seizures (limited role)

• Status epilepticus (phenobarbital, in refractory cases)

• Off-label use: trigeminal neuralgia (phenytoin), mood stabilization

---

Generic Names of Urea-Based Anticonvulsants

Compound Type	Generic Name
Hydantoins (ureide derivatives)	Phenytoin, Mephenytoin, Ethotoin
Barbiturates (ureide ring)	Phenobarbital
Barbiturate prodrugs	Primidone
Other related ureide AEDs	Metharbital, Aprobarbital

Detailed Pharmacological Profiles

---

1. Phenytoin

• Class: Hydantoin anticonvulsant (ureide-derived)

• Mechanism: Stabilizes neuronal membranes by selectively inhibiting voltage-gated sodium channels

• Use: Tonic-clonic seizures, partial seizures, status epilepticus (IV)

• Form: Oral capsules, chewable tablets, IV injection

• Dose: Typically 300–400 mg/day orally (maintenance); IV loading dose: 15–20 mg/kg

• Half-life: 22 hours (nonlinear kinetics)

• Monitoring: Serum levels (10–20 µg/mL therapeutic range)

• Adverse Effects:

  • Gingival hyperplasia

  • Hirsutism

  • Ataxia, nystagmus

  • Teratogenicity (fetal hydantoin syndrome)

  • SJS/TEN in HLA-B*1502 carriers (especially Asian populations)

• Drug Interactions:

  • Induces CYP3A4 → ↓ effectiveness of oral contraceptives, warfarin

  • Displacement of protein-bound drugs (e.g., valproate)

---

2. Phenobarbital

• Class: Barbiturate (ureide core structure)

• Mechanism: Enhances GABA-A receptor response; increases chloride influx into neurons

• Use: Generalized seizures, partial seizures, neonatal seizures, refractory status epilepticus

• Form: Oral tablet, IV, IM, syrup

• Dose: Adult: 60–120 mg/day; Neonatal: 15–20 mg/kg IV loading

• Half-life: 80–120 hours

• Advantages:

  • Inexpensive, long history of use

  • Effective monotherapy in resource-limited settings

• Disadvantages:

  • Sedation, cognitive impairment

  • Dependence and withdrawal

  • Induction of hepatic enzymes

• Drug Interactions: Potent CYP inducer; reduces levels of many other drugs

---

3. Primidone

• Class: Prodrug of phenobarbital; also a urea-derived anticonvulsant

• Mechanism: Converted into phenobarbital and phenylethylmalonamide (PEMA), both of which have anticonvulsant activity

• Use: Tonic-clonic and focal seizures; also used in essential tremor

• Form: Oral tablets

• Dose: 250–500 mg/day initially, titrated to 750–1500 mg/day

• Side Effects:

  • Sedation, dizziness

  • Nausea

  • Hematologic toxicity (rare)

---

4. Mephenytoin (Withdrawn or rarely used in many countries)

• Mechanism: Similar to phenytoin; metabolized into nirvanol (active metabolite)

• Use: Historically for tonic-clonic seizures

• Toxicity: High incidence of aplastic anemia, skin rashes

• Status: Withdrawn in the US and many other regions due to safety concerns

---

5. Ethotoin

• Mechanism: Sodium channel blocker

• Use: Generalized tonic-clonic and partial seizures

• Form: Oral

• Side Effects: Less toxic than phenytoin but less effective; sedation, GI upset

• Status: Limited use; not widely available

---

6. Metharbital / Aprobarbital

• Class: Barbiturates with mild anticonvulsant activity

• Use: Older agents used for focal seizures

• Status: Mostly obsolete due to adverse effects and more effective alternatives

---

Comparison of Key Properties

Agent	Primary Mechanism	Inducer/ Inhibitor	Therapeutic Range (µg/mL)	Notable Risk
Phenytoin	Na+ channel blocker	Strong inducer	10–20	Nonlinear kinetics, SJS/TEN
Phenobarbital	GABA-A enhancement	Strong inducer	15–40	Sedation, dependence
Primidone	Metabolized to phenobarbital	Strong inducer	—	Same as phenobarbital
Ethotoin	Na+ channel blocker	Mild inducer	15–50	GI upset, CNS sedation
Mephenytoin	Na+ channel blocker	Strong inducer	10–30	Aplastic anemia (withdrawn)

Adverse Effects (Class Summary)

• CNS: Sedation, dizziness, impaired cognition

• Dermatologic: Rash, Stevens-Johnson syndrome, TEN

• Hematologic: Rare aplastic anemia (mephenytoin)

• Hepatic: Enzyme induction → metabolic interactions

• Endocrine: Altered vitamin D metabolism → osteopenia

• Teratogenicity: Neural tube defects (phenytoin), fetal hydantoin syndrome

---

Contraindications and Precautions

Contraindication	Impacted Drug(s)
Porphyria	Barbiturates (e.g., phenobarbital)
Severe hepatic dysfunction	All urea AEDs (due to hepatic metabolism)
Pregnancy	Phenytoin, phenobarbital (category D)
HLA-B*1502 allele	Phenytoin (high risk of SJS/TEN in Asians)

Drug Interactions

• CYP450 induction: All agents (especially phenobarbital, phenytoin) induce CYP enzymes, leading to:

  • Decreased efficacy of oral contraceptives

  • Reduced warfarin levels (↓ INR)

  • Interactions with antiretrovirals, antifungals, and other AEDs

• Valproate: Inhibits phenytoin metabolism (↑ toxicity risk)

• Carbamazepine and phenytoin: Reduce each other's levels; avoid combination unless monitored closely

---

Monitoring Parameters

• Plasma drug levels (phenytoin, phenobarbital)

• Liver function tests

• CBC (for hematologic toxicity)

• Serum calcium and vitamin D (long-term use)

• Cognitive performance, mood, and suicidality screening

---

Modern Clinical Role and Limitations

Although the urea-based anticonvulsants played a pivotal role in early epilepsy management, their use has declined in favor of new-generation AEDs (e.g., levetiracetam, lamotrigine, lacosamide) due to:

• Lower side effect burden

• Fewer drug interactions

• Improved safety in pregnancy

However, they are still relevant in:

• Resource-limited settings

• Refractory epilepsy

• Neonatal seizures (phenobarbital)

• Essential tremor (primidone)